Cytotoxic: do not crush tablets.
| Pack |
|---|
| 28 tablet |
| 50 tablet |
| 100 tablet |
| Pack |
|---|
| 50 tablet |
| 56 tablet |
| 100 tablet |
| Pack |
|---|
| 1 vial |
Approved for treating SLE - commissined by NHSE.
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| 4 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
Mixed formulary colour coding:
AMBER (Shared care): capsules and liquid for shared care indications.
RED: injection and capsules for non-shared care indications.
Oral solution reserved for those with swallowing difficulties or specific clinical need.
Ciclosporin must be prescribed and dispensed by brand name.
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 30 capsule (6 x 5 capsules) |
| Pack |
|---|
| 50 ml |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
| Pack |
|---|
| 60 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 50 ml |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 50 ml |
| Pack |
|---|
| 10 ampoule |
| Pack |
|---|
| 10 ampoule |
| Pack |
|---|
| 60 capsule (6 x 10 capsules) |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
| Pack |
|---|
| 30 capsule (3 x 10 capsules) |
Fampyra is a branded option commissioned for prescribing.
Commissioned by NHSE.
| Pack |
|---|
| 28 tablet |
| 56 tablet |
Prescribe by brand to avoid confusion with mycophenolate mofetil.
AMBER for non-transplant indications
RED for all transplant indications
Mycophenolic acid is not recommended as an initial treatment to prevent organ rejection in adults having a kidney transplant (TA481).
Mycophenolic acid is not recommended as an initial treatment to prevent organ rejection in children and young people having a kidney transplant (TA482)
| Pack |
|---|
| 120 tablet (12 x 10 tablets) |
| Pack |
|---|
| 120 tablet (12 x 10 tablets) |
Mixed formulary colour coding:
AMBER (Shared care): capsules and tablets for non-transplant indications as per shared care documentation.
RED: injection and capsules and tablets for transplant indication.
Oral suspension reserved for those with swallowing difficulties or specific clinical need.
Prescribe by brand. When use to prevent transplant rejection, switching between a brand and generic formulation or between different generic formulations this should only be initiated by a transplant specialist.
| Pack |
|---|
| 100 capsule |
| Pack |
|---|
| 50 tablet |
| Pack |
|---|
| 175 ml |
| Pack |
|---|
| 100 capsule (10 x 10 capsules) |
| Pack |
|---|
| 50 tablet (5 x 10 tablets) |
| Pack |
|---|
| 4 vial |
Obinutuzumab plus mycophenolate mofetil can be used, within its marketing authorisation, as an option to treat active class 3 or 4 (with or without class 5) lupus nephritis in adults. (NICE TA1131)
| Pack |
|---|
| 1 vial |
Oral solution reserved for those with swallowing difficulties or specific clinical need.
Sirolimus is not recommended as an initial treatment to prevent organ rejection in adults having a kidney transplant (TA481)
Sirolimus is not recommended as an initial treatment to prevent organ rejection in children and young people having a kidney transplant (TA482)
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| 100 tablet |
| Pack |
|---|
| 30 tablet |
| 100 tablet |
| Pack |
|---|
| 60 ml |
Prescribe by brand. When use to prevent transplant rejection, switching between a brand and generic formulation or between different generic formulations this should only be initiated by a transplant specialist.
Prolonged release tacrolimus is not recommended as an initial treatment to prevent organ rejection in adults having a kidney transplant (TA481)
Prolonged release tacrolimus is not recommended as an initial treatment to prevent organ rejection in children and young people having a kidney transplant (TA482)
In Coastal West Sussex only tacrolimus is approved as a third line option for treating immunological diseases of the oral cavity. This is unlicensed use achieved by dissolution in water and use of this as a mouthwash
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 30 capsule |
| 60 capsule |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| 100 capsule (10 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| 100 capsule (10 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 capsule (5 x 10 capsules) |
| Pack |
|---|
| 50 sachet |
| Pack |
|---|
| 50 sachet |
| Pack |
|---|
| 50 capsule |
| Pack |
|---|
| 50 capsule |
| 100 capsule |
| Pack |
|---|
| 50 capsule |






